|Videos|June 11, 2021
Ulcerative Colitis: Goals of Treatment
Maria T. Abreu, MD, of the University of Miami Health System, explains how goals of treatment for ulcerative colitis have changed in recent years and reacts to changes in managing the disease.
Advertisement
Episodes in this series
Advertisement
Related to this article
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Advertisement
Advertisement
Trending on HCPLive
1
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
2
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
3
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
4
IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy
5